2. Epigenetics TGF-beta/Smad Stem Cell/Wnt Apoptosis Anti-infection
  3. PKC PKA Apoptosis Bacterial Fungal Antibiotic
  4. Staurosporine

Staurosporine  (Synonyms: Antibiotic AM-2282; STS; AM-2282)

Cat. No.: HY-15141 Purity: 99.52%
COA
SDS
Handling Instructions Technical Support

Staurosporine est un inhibiteur puissant et non sélectif des protéines kinases avec des IC50s de 6 nM, 15 nM, 2 nM et 3 nM pour PKC, PKA, c-Fgr et Phosphorylase kinase respectivement.

Staurosporin ist ein wirksamer und nicht selektiver Inhibitor von Proteinkinasen mit IC50-Werten von 6 nM, 15 nM, 2 nM und 3 nM für PKC-, PKA-, c-Fgr- bzw. Phosphorylase-Kinase.

Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer.

For research use only. We do not sell to patients.

CAS No. : 62996-74-1

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
2 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 207 publication(s) in Google Scholar

Other Forms of Staurosporine:

Staurosporine Related Antibodies

Top Publications Citing Use of Products

207 Publications Citing Use of MCE Staurosporine

WB

    Staurosporine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Oct 9;5(1):235.  [Abstract]

    Mock-treated or SARS-CoV-2 (MOI = 0.1)-infected Calu-3 cells were collected at 48 h post infection and subjected to western blotting using the indicated antibodies. Cells treated with staurosporine (STS, 1 μM) for 24 h were used as a positive control. The arrow indicates the specific band of cleaved caspase-9.

    Staurosporine purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2020 Aug;17(8):881-883.  [Abstract]

    HEK293T cells were transfected with empty vector or FLAG-SARS-CoV-2 ORF3a. After 12 and 24 h, cells were subjected to western blotting analysis using the indicated antibodies. Cells treated with STS for 5 h were used as a positive control. STS, staurosporine.

    Staurosporine purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 Aug;1864(8):2600-2609.  [Abstract]

    Expression of Nogo-B and apoptosis-related proteins determined by Western blot analysis.

    Staurosporine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2017 Sep:50:30-37.  [Abstract]

    BV-2 cells are pretreated with or without Staurosporine (1 μM) for 30 min, and then incubated with 20 μM Aβ1–42 for 24 h. The protein expression of TNF-α, IL-1β, and IL-6 are detected by western blot.

    Staurosporine purchased from MedChemExpress. Usage Cited in: Neuroscience. 2017 Dec 4:365:217-225.  [Abstract]

    PMA markedly reduces the protein level of GLT-1.

    Staurosporine purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 Apr 15;73(8):2574-86.  [Abstract]

    Cells are treated with the indicated concentrations of AZD8055, Torin2 or staurosporin overnight and analyzed by western blot using antibodies specific for the indicated proteins.

    View All PKC Isoform Specific Products:

    View All Isoforms
    PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

    View All PKA Isoform Specific Products:

    View All Isoforms
    PKA PKAR PKACα

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases with IC50s of 6 nM, 15 nM, 2 nM, and 3 nM for PKC, PKA, c-Fgr, and Phosphorylase kinase respectively. Staurosporine also inhibits TAOK2 with an IC50 of 3 μM. Staurosporine is an apoptosis inducer[1][2][3][4][5].

    IC50 & Target[1]

    PKC

    6 nM (IC50)

    PKA

    15 nM (IC50)

    c-Fgr

    2 nM (IC50)

    Phosphorylase kinase

    3 nM (IC50)

    S6 kinase (70 kDa)

    5 nM (IC50)

    v-Src

    6 nM (IC50)

    cdc2

    9 nM (IC50)

    TPK-IIB/Syk

    16 nM (IC50)

    Ca2+/CaM PK-I1

    20 nM (IC50)

    MLCK

    21 nM (IC50)

    IR

    61 nM (IC50)

    EGF-R

    100 nM (IC50)

    ERK-1

    1500 nM (IC50)

    CSK

    2000 nM (IC50)

    IGF-IR

    6150 nM (IC50)

    CK2

    19500 nM (IC50)

    CK1

    163500 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    518A2 EC50
    0.03 μM
    Compound: STS
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    518A2 IC50
    0.2 μM
    Compound: STP
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    8505C IC50
    0.2 μM
    Compound: STP
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    A-375 IC50
    2.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    Antiproliferative activity against human A-375 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    		[PMID: 35196017]
    A-431 IC50
    70 nM
    Compound: Staurosporine
    Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay
    Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay
    		[PMID: 22541051]
    A2780 EC50
    0.1 μM
    Compound: STS
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    A2780 EC50
    0.1 μM
    Compound: Staurosporine
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    A2780 EC50
    0.12 μM
    Compound: STS
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    A2780 IC50
    0.1 μM
    Compound: ST
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    A2780 IC50
    0.2 μM
    Compound: STP
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    A549 EC50
    0.04 μM
    Compound: STS
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    A549 GI50
    2.4 nM
    Compound: staurosporine
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method
    Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method
    		[PMID: 18484775]
    A549 IC50
    0.002 μM
    Compound: Staurosporine
    Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth
    Anticancer activity against human A549 cells harboring KRAS mutant assessed as inhibition of cell growth
    		[PMID: 38199330]
    A549 IC50
    0.02 μM
    Compound: staurosporine
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 25825934]
    A549 IC50
    0.02 μM
    Compound: Staurosporine
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
    		10.1039/C2MD20098H
    A549 IC50
    0.6 μM
    Compound: STP
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    Cytotoxicity against human A549 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    A549 IC50
    13.22 μM
    Compound: Staurosporine
    Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    Antiproliferative activity against human A549 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    		[PMID: 31794211]
    A549 IC50
    139.95 ng/mL
    Compound: Staurosporine
    Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
    Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
    		[PMID: 19138858]
    A549 IC50
    139.95 ng/mL
    Compound: Staurosporine
    Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
    Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
    		[PMID: 19138858]
    A549 IC50
    3.05 μM
    Compound: Staurosporine
    Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells after 24 to 48 hrs by CCK-8 assay
    		[PMID: 24792811]
    A549 IC50
    7.47 μM
    Compound: Staurosporine
    Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay
    Antiproliferative activity against human A549 cells measured after 72 hrs under normoxic condition by MTT assay
    		[PMID: 31794211]
    A549 IC50
    9.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    		[PMID: 35196017]
    A549 IC50
    9.5 μM
    Compound: Staurosporine
    Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability measured by MTT assay
    		[PMID: 34246754]
    B16-F10 IC50
    2.82 μM
    Compound: Staurosporine
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay
    		[PMID: 22503364]
    BGC-823 EC50
    26.83 μg/mL
    Compound: Staurosporine
    Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay
    Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay
    		[PMID: 21889345]
    BGC-823 IC50
    0.38 μM
    Compound: Staurosporine
    Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    		[PMID: 24328283]
    BGC-823 IC50
    6.83 μM
    Compound: Staurosporine
    Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method
    Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method
    		[PMID: 23018096]
    BJ EC50
    < 2 μM
    Compound: Staurosporine
    Cytotoxicity against human BJ cells
    Cytotoxicity against human BJ cells
    		[PMID: 25316317]
    BJ EC50
    > 40 μM
    Compound: STS
    Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human BJ cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    BJ IC50
    0.002 μM
    Compound: Staurosporine
    Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay
    Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay
    		[PMID: 22921081]
    BT-549 IC50
    0.08 μM
    Compound: Staurosporine
    Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay
    Cytotoxic activity against human BT549 cells incubated for 24 hrs by MTT assay
    		[PMID: 28705432]
    CAPAN-1 IC50
    0.0123 μM
    Compound: Staurosporine
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    CAPAN-1 IC50
    0.03 μM
    Compound: STS
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    CAPAN-1 IC50
    0.048 μM
    Compound: Staurosporine
    Antiproliferative activity against human Capan1 cells
    Antiproliferative activity against human Capan1 cells
    		[PMID: 31005446]
    CAPAN-1 IC50
    0.0546 μM
    Compound: Staurosporine
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    		[PMID: 34352711]
    CAPAN-1 IC50
    0.66 μM
    Compound: Staurosporine
    Cytostatic activity against human Capan1 cells
    Cytostatic activity against human Capan1 cells
    		[PMID: 30738653]
    CCRF-CEM IC50
    0.023 μM
    Compound: Staurosporine
    Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay
    Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay
    		[PMID: 22921081]
    CHO-K1 GI50
    0.13 μM
    Compound: Staurosporine
    Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay
    Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay
    		[PMID: 21513294]
    COLO 205 IC50
    < 0.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31740249]
    Ca-Ski IC50
    0.01144 μM
    Compound: Staurosporine
    Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human Ca-Ski cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 34656041]
    DLD-1 IC50
    0.009 μM
    Compound: Staurosporine
    Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay
    Antiproliferative activity against human colon cancer cell line (DLD-1 cells) using MTT assay
    		[PMID: 11591505]
    DLD-1 IC50
    0.009 μM
    Compound: Staurosporine
    Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay
    		[PMID: 22182929]
    DU-145 IC50
    0.5 μM
    Compound: Staurosporine
    Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay
    Induction of mitochondrial membrane potential loss in human DU145 cells after 2 hrs by JC1 staining based fluorescence assay
    		[PMID: 31120251]
    FHC GI50
    32.65 μM
    Compound: Staurosporine
    Cytotoxicity against human FHC cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human FHC cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    FaDu EC50
    0.1 μM
    Compound: Staurosporine
    Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human FaDu cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    FaDu EC50
    0.2 μM
    Compound: STS
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    FaDu IC50
    0.1 μM
    Compound: ST
    Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    HCT-116 GI50
    6.31 μM
    Compound: Staurosporine
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    HCT-116 IC50
    0.006 μM
    Compound: Staurosporine
    Concentration required for growth inhibition of human colon carcinoma cell line HCT116
    Concentration required for growth inhibition of human colon carcinoma cell line HCT116
    		[PMID: 15537345]
    HCT-116 IC50
    0.0281 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HCT-116 IC50
    0.03 μM
    Compound: Staurosporine
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 30106291]
    HCT-116 IC50
    0.037 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT116 cells
    Antiproliferative activity against human HCT116 cells
    		[PMID: 31005446]
    HCT-116 IC50
    0.04 μM
    Compound: STS
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HCT-116 IC50
    0.0481 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    		[PMID: 34352711]
    HCT-116 IC50
    0.055 μM
    Compound: Staurosporine
    Cytotoxicity against human HCT116 cells by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells by sulforhodamine B assay
    		[PMID: 29389122]
    HCT-116 IC50
    13.2 μM
    Compound: Staurosporine
    Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0306-5
    HCT-116 IC50
    16.15 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    Antiproliferative activity against human HCT116 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    		[PMID: 31794211]
    HCT-116 IC50
    32.57 μg/mL
    Compound: Staurosporine
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based assay
    		[PMID: 37224699]
    HCT-116 IC50
    39 nM
    Compound: Staurosporine
    Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay
    Inhibition of TNIK-mediated TCF4/beta-casein transcription in human HCT116 cells by beta-lactamase reporter gene assay
    		[PMID: 23232060]
    HCT-116 IC50
    6.94 μM
    Compound: Staurosporine
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 35694689]
    HCT-116 IC50
    8.86 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay
    Antiproliferative activity against human HCT116 cells measured after 72 hrs under normoxic condition by MTT assay
    		[PMID: 31794211]
    HCT-116 IC50
    < 0.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31740249]
    HEK293 CC50
    0.00354 μM
    Compound: Staurosporine
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay
    Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 72 hrs by CellTiter Glo luminescent assay
    		[PMID: 28624701]
    HEK293 EC50
    < 2 μM
    Compound: Staurosporine
    Cytotoxicity against HEK293 cells
    Cytotoxicity against HEK293 cells
    		[PMID: 25316317]
    HEK293 GI50
    9.25 μM
    Compound: Staurosporine
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    HEK293 IC50
    0.0037 μM
    Compound: Staurosporine
    Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)
    Cytotoxicity against human HEK293 cells assessed as cell viability incubated for 72 hrs by cell titer-glo luminescent cell viability assay (Rvb = > 100 uM)
    		[PMID: 31252285]
    HEK293 IC50
    0.056 μM
    Compound: Staurosporine
    Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay
    Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay
    		[PMID: 24763262]
    HEK293 IC50
    0.077 μM
    Compound: Staurosporine
    Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2
    Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2
    		[PMID: 15771419]
    HEK293 IC50
    0.077 μM
    Compound: staurosporine
    Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA
    Inhibition of PKC-beta II mediated IL-8 release from HEK293 cells by ELISA
    		[PMID: 12941331]
    HEK293 IC50
    0.41 μM
    Compound: Staurosporine
    Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
    Antiproliferative activity against HEK293 cells assessed as inhibition rate incubated for 72 hrs by MTT assay
    		[PMID: 34844412]
    HEK293 IC50
    34.33 μM
    Compound: Staurosporine
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability by MTT assay
    		[PMID: 35182815]
    HL-60 IC50
    0.0076 μM
    Compound: Staurosporine
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    HL-60 IC50
    0.019 μM
    Compound: Staurosporine
    Antiproliferative activity against human HL60 cells
    Antiproliferative activity against human HL60 cells
    		[PMID: 31005446]
    HL-60 IC50
    0.04 μM
    Compound: STS
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    HL-60 IC50
    0.041 μM
    Compound: Staurosporine
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    HL-60 IC50
    9.24 μM
    Compound: Staurosporine
    Cytostatic activity against human HL60 cells
    Cytostatic activity against human HL60 cells
    		[PMID: 30738653]
    HMLE IC50
    4.9 nM
    Compound: 1
    Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay
    Cytotoxicity against human HMLE cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay
    		[PMID: 33335665]
    HOP-92 GI50
    9.99 μM
    Compound: Staurosporine
    Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    HT-29 EC50
    0.15 μM
    Compound: STS
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    HT-29 EC50
    0.2 μM
    Compound: STS
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    HT-29 EC50
    0.2 μM
    Compound: Staurosporine
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    HT-29 ED50
    0.0026 μM
    Compound: Staurosporine
    Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay
    Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay
    		[PMID: 21973101]
    HT-29 ED50
    2.6 nM
    Compound: staurosporine
    Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay
    Induction of apoptosis in human HT-29 cells assessed as change in mitochondrial transmembrane potential after 2 hrs by JC1 staining based fluorescence assay
    		[PMID: 19422206]
    HT-29 ED50
    > 20 μM
    Compound: Staurosporine
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    		[PMID: 21973101]
    HT-29 GI50
    10.9 nM
    Compound: staurosporine
    Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method
    Cytotoxicity against human HT29 cells after 72 hrs by sulforhodamine B method
    		[PMID: 18484775]
    HT-29 GI50
    3.6 μM
    Compound: Staurosporine
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
    		[PMID: 21513294]
    HT-29 IC50
    0.01 μM
    Compound: STS
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth
    		[PMID: 32201021]
    HT-29 IC50
    0.2 μM
    Compound: ST
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    HT-29 IC50
    0.2 μM
    Compound: STP
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    HT-29 IC50
    2 nM
    Compound: Staurosporine
    Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay
    Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay
    		[PMID: 21428375]
    HT-29 IC50
    2.5 nM
    Compound: Staurosporine
    Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay
    Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay
    		[PMID: 21513293]
    HT-29 IC50
    20 nM
    Compound: Staurosporine
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
    		[PMID: 30057155]
    HUVEC IC50
    0.004 μM
    Compound: Staurosporine
    Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay
    Antiproliferative activity against human umbilical vein endothelial cells (HUVECs) using MTT assay
    		[PMID: 11591505]
    HUVEC IC50
    0.004 μM
    Compound: Staurosporine
    Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay
    		[PMID: 22182929]
    HUVEC IC50
    0.5 μM
    Compound: STS
    Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against HUVEC cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 34671737]
    HaCaT IC50
    1.6 μM
    Compound: Staurosporine
    Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    Antiproliferative activity against human HaCaT cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    		[PMID: 35196017]
    HeLa EC50
    29.12 μg/mL
    Compound: Staurosporine
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21889345]
    HeLa IC50
    0.025 μM
    Compound: staurosporine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 25825934]
    HeLa IC50
    0.025 μM
    Compound: Staurosporine
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
    		10.1039/C2MD20098H
    HeLa IC50
    0.175 μM
    Compound: Staurosporine
    Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay
    Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay
    		[PMID: 22921081]
    HeLa IC50
    2.72 μM
    Compound: Staurosporine
    Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells after 24 to 48 hrs by CCK-8 assay
    		[PMID: 24792811]
    HeLa IC50
    4 pM
    Compound: Staurosporine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21388191]
    HeLa IC50
    4 pM
    Compound: Staurosporine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21488655]
    HeLa IC50
    9.12 μM
    Compound: Staurosporine
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT method
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT method
    		[PMID: 23018096]
    HeLa S3 IC50
    4 pM
    Compound: Staurosporine
    Cytotoxicity against human HeLa S3 cells measured after 72 hrs
    Cytotoxicity against human HeLa S3 cells measured after 72 hrs
    		[PMID: 32688198]
    HepG2 EC50
    21.74 μg/mL
    Compound: Staurosporine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21889345]
    HepG2 EC50
    < 2 μM
    Compound: Staurosporine
    Cytotoxicity against human HepG2 cells
    Cytotoxicity against human HepG2 cells
    		[PMID: 25316317]
    HepG2 IC50
    0.018 μM
    Compound: Staurosporine
    Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human HepG2 cells at 100 uM after 3 days by CellTiter-Glo luminescent cell viability assay
    		[PMID: 28993106]
    HepG2 IC50
    4.14 μM
    Compound: Staurosporine
    Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay
    Inhibition of telomerase in human HepG2 cells after 24 hrs by TRAP-PCR-ELISA assay
    		[PMID: 23018096]
    HepG2 IC50
    5.07 μM
    Compound: Staurosporine
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36848846]
    HepG2 IC50
    6.73 μM
    Compound: Staurosporine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method
    		[PMID: 23018096]
    HepG2 IC50
    8.3 μM
    Compound: Staurosporine
    Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA
    Inhibition of telomerase in human HepG2 cells after 48 hrs by TRAP-PCR-ELISA
    		[PMID: 23279864]
    HepG2 IC50
    9.04 μM
    Compound: Staurosporine
    Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0306-5
    Huh-7 IC50
    0.23 μM
    Compound: Staurosporine
    Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    		[PMID: 24328283]
    Jurkat IC50
    0.003 μM
    Compound: Staurosporine
    Inhibitory activity against protein kinase C from Jurkat cells.
    Inhibitory activity against protein kinase C from Jurkat cells.
    		10.1016/S0960-894X(01)80408-X
    Jurkat IC50
    0.0393 μM
    Compound: Staurosporine
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    Jurkat IC50
    0.14 μM
    Compound: Staurosporine
    Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    Cytotoxicity against human Jurkat cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    		[PMID: 24328283]
    Jurkat IC50
    3.2 μM
    Compound: Staurosporine
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    		[PMID: 35196017]
    Jurkat IC50
    311 nM
    Compound: staurosporine
    Antiproliferative activity against JAK3 expressing human resting Jurkat cells
    Antiproliferative activity against JAK3 expressing human resting Jurkat cells
    		[PMID: 19427203]
    Jurkat IC50
    71 nM
    Compound: staurosporine
    Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells
    Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells
    		[PMID: 19427203]
    K562 IC50
    0.04 μM
    Compound: STS
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    K562 IC50
    0.0768 μM
    Compound: Staurosporine
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    K562 IC50
    0.083 μM
    Compound: Staurosporine
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 31005446]
    K562 IC50
    1.7 μM
    Compound: Staurosporine
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 30106291]
    K562 IC50
    153 μM
    Compound: STSP
    Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Antitumor activity against human K562 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    		[PMID: 26022079]
    K562 IC50
    23.1 μM
    Compound: Staurosporine
    Cytostatic activity against human K562 cells
    Cytostatic activity against human K562 cells
    		[PMID: 30738653]
    K562 IC50
    > 0.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    KB ED50
    0.0024 μg/mL
    Compound: 1
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 3204380]
    KB 3-1 IC50
    < 0.2 μM
    Compound: Staurosporine
    Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay
    Antiproliferative activity against human KB-3-1 cells after 5 days by WST-1 assay
    		[PMID: 28956915]
    KOPN-8 EC50
    0.71 μM
    Compound: STS
    Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human KOPN8 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    L02 IC50
    9.5 μM
    Compound: Staurosporine
    Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 30106291]
    L929 IC50
    < 0.2 μM
    Compound: Staurosporine
    Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay
    Antiproliferative activity against mouse L929 cells after 5 days by WST-1 assay
    		[PMID: 28956915]
    LN-229 IC50
    0.003 μM
    Compound: STS
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    LN-229 IC50
    0.0097 μM
    Compound: Staurosporine
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    		[PMID: 34352711]
    LOX IMVI IC50
    7.15 μM
    Compound: Staurosporine
    Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human LOX IMVI cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 33601311]
    Leukemia cell EC50
    0.35 μM
    Compound: STS
    Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against mouse leukemia cells overexpressing BCR/ABL after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    LoVo IC50
    0.001 μM
    Compound: Staurosporine
    Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay
    Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay
    		[PMID: 11591505]
    LoVo IC50
    0.001 μM
    Compound: Staurosporine
    Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay
    		[PMID: 22182929]
    MCF-10A IC50
    18.01 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38107182]
    MCF7 EC50
    0.1 μM
    Compound: STS
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    MCF7 EC50
    0.1 μM
    Compound: STS
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    MCF7 EC50
    0.1 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    MCF7 GI50
    11 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 21513294]
    MCF7 IC50
    0.013 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		10.1039/C2MD20098H
    MCF7 IC50
    0.02 μM
    Compound: STS
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
    		[PMID: 32201021]
    MCF7 IC50
    0.064 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay
    Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay
    		[PMID: 22921081]
    MCF7 IC50
    0.1 μM
    Compound: ST
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    MCF7 IC50
    0.33 μM
    Compound: Staurosporine
    Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA
    Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA
    		[PMID: 31992477]
    MCF7 IC50
    0.4 μM
    Compound: STP
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    MCF7 IC50
    0.52 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    Cytotoxicity against human MCF7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay
    		[PMID: 24328283]
    MCF7 IC50
    1.8 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay
    Antiproliferative activity against human MCF7 cells after 5 days by WST-1 assay
    		[PMID: 28956915]
    MCF7 IC50
    16.06 μM
    Compound: Staurosporine
    Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by MTT assay
    		10.1007/s00044-012-0306-5
    MCF7 IC50
    180 nM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay
    		[PMID: 22541051]
    MCF7 IC50
    2 μM
    Compound: Staurosporine
    Inhibition of PKA in human MCF7 cells by array-based fluorescence assay
    Inhibition of PKA in human MCF7 cells by array-based fluorescence assay
    		[PMID: 18656369]
    MCF7 IC50
    3.07 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 22503364]
    MCF7 IC50
    3.144 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 38283222]
    MCF7 IC50
    3.18 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 37501287]
    MCF7 IC50
    3.39 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxic condition by MTT assay
    		[PMID: 31972394]
    MCF7 IC50
    3.67 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay
    		[PMID: 32877804]
    MCF7 IC50
    3.67 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay
    		[PMID: 33667848]
    MCF7 IC50
    4.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    		[PMID: 34482273]
    MCF7 IC50
    4.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
    		[PMID: 34871842]
    MCF7 IC50
    50 nM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21388191]
    MCF7 IC50
    50 nM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21488655]
    MCF7 IC50
    6.08 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 3 days by MTT assay
    		[PMID: 34743062]
    MCF7 IC50
    6.3 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by colorimetric based MTT assay
    		[PMID: 35196017]
    MCF7 IC50
    6.76 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36848846]
    MCF7 IC50
    7.25 μM
    Compound: Staurosporine
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 35694689]
    MCF7 IC50
    7.33 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay
    		[PMID: 32877804]
    MCF7 IC50
    8.81 μM
    Compound: Staurosporine
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 3 days by MTT assay
    		[PMID: 31992477]
    MCF7 IC50
    9.2 μM
    Compound: Staurosporine
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay
    		[PMID: 31972394]
    MDA-MB-231 GI50
    7.1 nM
    Compound: staurosporine
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method
    		[PMID: 18484775]
    MDA-MB-231 IC50
    0.00085 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 34656041]
    MDA-MB-231 IC50
    0.01 μM
    Compound: Staurosporin
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    0.24 μM
    Compound: Staurosporine
    Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    Cytotoxic activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay
    		[PMID: 28705432]
    MDA-MB-231 IC50
    2.5 nM
    Compound: 1
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell metabolic activity after 72 hrs by MTS assay
    		[PMID: 33335665]
    MDA-MB-231 IC50
    4.25 μM
    Compound: Staurosporine
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
    		[PMID: 32044580]
    MDA-MB-231 IC50
    4.31 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under normaxic condition by MTT assay
    		[PMID: 32877804]
    MDA-MB-231 IC50
    4.385 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 38283222]
    MDA-MB-231 IC50
    6.75 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs under chemically-induced hypoxic condition by MTT assay
    		[PMID: 32877804]
    MDA-MB-231 IC50
    6.75 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 2 days by MTT assay
    		[PMID: 33667848]
    MDA-MB-453 IC50
    0.02351 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 34656041]
    MDA-MB-468 IC50
    0.005 μM
    Compound: STS
    Antiproliferative activity against human MDA-MB-468 cells assessed inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-468 cells assessed inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37037136]
    MDA-MB-468 IC50
    0.15 μM
    Compound: Staurosporine
    Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay
    Cytotoxic activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay
    		[PMID: 28705432]
    MDA-MB-468 IC50
    4.37 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under normoxic condition by MTT assay
    		[PMID: 31972394]
    MDA-MB-468 IC50
    6.358 μM
    Compound: Staurosporine
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38107182]
    MDA-MB-468 IC50
    6.46 μM
    Compound: Staurosporine
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay
    Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs under CoCl2-induced hypoxic condition by MTT assay
    		[PMID: 31972394]
    MGC-803 IC50
    8.97 μM
    Compound: Staurosporine
    Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay
    Inhibition of telomerase in human MGC-803 cells after 24 hrs by TRAP-PCR-ELISA assay
    		[PMID: 26900656]
    MIA PaCa-2 IC50
    370 nM
    Compound: Staurosporine
    Antiproliferative activity against MiaPaCa-2 cells by MTT assay
    Antiproliferative activity against MiaPaCa-2 cells by MTT assay
    		[PMID: 16403626]
    MIA PaCa-2 IC50
    370 nM
    Compound: Staurosporine
    Antiproliferative activity against human MiaPaCa-2 cells
    Antiproliferative activity against human MiaPaCa-2 cells
    		[PMID: 16413780]
    MM1.S IC50
    0.0442 μM
    Compound: Staurosporine
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    MRC5 GI50
    27.27 μM
    Compound: Staurosporine
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human MRC5 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    MV4-11 IC50
    0.05 μM
    Compound: Staurosporine
    Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Cytotoxicity against human MV4-11cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    N2a IC50
    0.0113 μM
    Compound: Staurosporine
    Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse Neuro2a cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 28152427]
    NALM-6 EC50
    1.4 μM
    Compound: STS
    Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human NALM6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    NCI-H1975 IC50
    0.005 μM
    Compound: Staurosporine
    Anticancer activity against TKI resistant human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth
    Anticancer activity against TKI resistant human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth
    		[PMID: 38199330]
    NCI-H460 GI50
    3.6 μM
    Compound: Staurosporine
    Cytotoxicity against human H460 cells after 48 hrs by SRB assay
    Cytotoxicity against human H460 cells after 48 hrs by SRB assay
    		[PMID: 21513294]
    NCI-H460 IC50
    0.024 μM
    Compound: Staurosporine
    Antiproliferative activity against human NCI-H460 cells
    Antiproliferative activity against human NCI-H460 cells
    		[PMID: 31005446]
    NCI-H460 IC50
    0.0597 μM
    Compound: Staurosporine
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    NCI-H460 IC50
    0.06 μM
    Compound: STS
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    NCI-H460 IC50
    11.5 μM
    Compound: Staurosporine
    Cytostatic activity against human NCI-H460 cells
    Cytostatic activity against human NCI-H460 cells
    		[PMID: 30738653]
    NCI-H460 IC50
    > 0.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
    		[PMID: 34352711]
    NIH3T3 EC50
    0.008 μM
    Compound: STS
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    		[PMID: 29197730]
    NIH3T3 EC50
    0.008 μM
    Compound: STS
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    NIH3T3 EC50
    0.008 μM
    Compound: Staurosporine
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
    		[PMID: 33049606]
    NIH3T3 IC50
    0.008 μM
    Compound: ST
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 32422522]
    NIH3T3 IC50
    0.2 μM
    Compound: STP
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
    		[PMID: 24361521]
    NIH3T3 IC50
    140.12 μM
    Compound: Staurosporine
    Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    		[PMID: 24286761]
    P19 IC50
    0.002 μM
    Compound: Staurosporine
    Inhibition of Platelet-derived growth factor receptor in P19 cells
    Inhibition of Platelet-derived growth factor receptor in P19 cells
    		[PMID: 15771419]
    P19 IC50
    0.004 μM
    Compound: Staurosporine
    Inhibition of Protein Kinase A in P19 cells
    Inhibition of Protein Kinase A in P19 cells
    		[PMID: 15771419]
    P19 IC50
    0.006 μM
    Compound: Staurosporine
    Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells
    Inhibition of Calcium/calmodulin-dependent protein kinase type II in P19 cells
    		[PMID: 15771419]
    P19 IC50
    0.008 μM
    Compound: Staurosporine
    Inhibition of Cyclin-dependent kinase 1 in P19 cells
    Inhibition of Cyclin-dependent kinase 1 in P19 cells
    		[PMID: 15771419]
    P19 IC50
    0.014 μM
    Compound: Staurosporine
    Inhibition of Vascular endothelial growth factor receptor in P19 cells
    Inhibition of Vascular endothelial growth factor receptor in P19 cells
    		[PMID: 15771419]
    P19 IC50
    0.2 μM
    Compound: Staurosporine
    Inhibition of Insulin receptor kinase in P19 cells
    Inhibition of Insulin receptor kinase in P19 cells
    		[PMID: 15771419]
    P19 IC50
    1.4 μM
    Compound: Staurosporine
    Inhibition of Casein kinase 1 in P19 cells
    Inhibition of Casein kinase 1 in P19 cells
    		[PMID: 15771419]
    P19 IC50
    > 10 μM
    Compound: Staurosporine
    Inhibition of Casein kinase 2 of P19 cells
    Inhibition of Casein kinase 2 of P19 cells
    		[PMID: 15771419]
    P19 IC50
    > 10 μM
    Compound: Staurosporine
    Inhibition of Epidermal growth factor receptor in P19 cells
    Inhibition of Epidermal growth factor receptor in P19 cells
    		[PMID: 15771419]
    P19 IC50
    > 10 μM
    Compound: Staurosporine
    Inhibition of Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 in P19 cells
    Inhibition of Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 in P19 cells
    		[PMID: 15771419]
    P388 ED50
    < 0.08 μg/mL
    Compound: 1
    Cytotoxicity against mouse P388 cells
    Cytotoxicity against mouse P388 cells
    		[PMID: 3204380]
    PANC-1 IC50
    0.02 μM
    Compound: STS
    Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth
    Antiproliferative activity against human PANC1 cells assessed as inhibition of cell growth
    		[PMID: 32201021]
    PBMC IC50
    0.0002 μM
    Compound: Staurosporine
    Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay
    Cytotoxicity against human PBMC cells assessed as inhibition of cell proliferation measured after 72 hrs by radioactive cell proliferation assay
    		[PMID: 33248847]
    PBMC IC50
    0.016 μM
    Compound: 1
    Suppression of IL2 production in human PBMC after 24 hrs by ELISA
    Suppression of IL2 production in human PBMC after 24 hrs by ELISA
    		[PMID: 18585046]
    PBMC IC50
    0.016 μM
    Compound: staurosporine
    Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA
    Inhibition of IL2 production in PHA-stimulated human PBMC after 24 hrs by ELISA
    		[PMID: 18823784]
    PC-3 IC50
    0.017 μM
    Compound: Staurosporine
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    Cytotoxicity against human PC3 cells by sulforhodamine B assay
    		[PMID: 29389122]
    PC-3 IC50
    0.031 μM
    Compound: staurosporine
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 25825934]
    PC-3 IC50
    0.039 μM
    Compound: STU
    Cytotoxicity against human PC3 cells after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 72 hrs by SRB assay
    		[PMID: 29558119]
    PC-3 IC50
    0.36 μM
    Compound: Staurosporine
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 36848846]
    PC-3 IC50
    4.91 μM
    Compound: Staurosporine
    Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay
    Antiproliferative activity against human PC3 cells measured after 72 hrs under normoxic condition by MTT assay
    		[PMID: 31794211]
    PC-3 IC50
    5.92 μM
    Compound: Staurosporine
    Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    Antiproliferative activity against human PC3 cells measured after 72 hrs under CoCl2-induced hypoxic condition by MTT assay
    		[PMID: 31794211]
    Platelet IC50
    48 nM
    Compound: Staurosporine
    Inhibition of alpha-thrombin induced human Platelet aggregation pre-incubated for 1 min followed by alpha-thrombin stimulation and measured after 30 sec by aggregometer assay
    Inhibition of alpha-thrombin induced human Platelet aggregation pre-incubated for 1 min followed by alpha-thrombin stimulation and measured after 30 sec by aggregometer assay
    		[PMID: 1874734]
    Platelet IC50
    76 nM
    Compound: Staurosporine
    Inhibition of collagen induced human Platelet aggregation pre-incubated for 1 min followed by collagen stimulation and measured after 30 sec by aggregometer assay
    Inhibition of collagen induced human Platelet aggregation pre-incubated for 1 min followed by collagen stimulation and measured after 30 sec by aggregometer assay
    		[PMID: 1874734]
    RBL-2H3 IC50
    0.2 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA
    		[PMID: 30711393]
    RBL-2H3 IC50
    0.3 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA
    		[PMID: 30711393]
    RBL-2H3 IC50
    0.3 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta-glucopyranoside dye-based colorimetric analysis
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta-glucopyranoside dye-based colorimetric analysis
    		[PMID: 30711393]
    RBL-2H3 IC50
    0.3 μM
    Compound: Staurosporine
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside substrate based colorimetric method
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of mouse anti-DNP IgE-stimulated beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside substrate based colorimetric method
    		[PMID: 31879206]
    RBL-2H3 IC50
    0.5 μM
    Compound: Staurosporine
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of anti-DNP IgE-stimulated TNFalpha release preincubated for 15 mins followed by mouse anti-DNP IgE stimulation and measured after 3 hrs by ELISA
    		[PMID: 31879206]
    RBL-2H3 IC50
    0.7 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA
    		[PMID: 30711393]
    RBL-2H3 IC50
    0.8 μM
    Compound: Staurosporine
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside substrate based colorimetric method
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated beta-hexosaminidase release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by 4-nitropheny1-2-acetamide-2-deoxy-beta-glucopyranoside substrate based colorimetric method
    		[PMID: 31879206]
    RBL-2H3 IC50
    1 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA
    		[PMID: 30711393]
    RBL-2H3 IC50
    1 μM
    Compound: Staurosporine
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta-glucopyranoside dye-based colorimetric analysis
    Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta-glucopyranoside dye-based colorimetric analysis
    		[PMID: 30711393]
    RBL-2H3 IC50
    1 μM
    Compound: Staurosporine
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA
    Inhibition of PKC in rat RBL2H3 cells assessed as inhibition of ionomycin-stimulated TNFalpha release preincubated for 15 mins followed by ionomycin stimulation and measured after 3 hrs by ELISA
    		[PMID: 31879206]
    RXF 393 GI50
    0.95 μM
    Compound: Staurosporine
    Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    Raji EC50
    < 2 μM
    Compound: Staurosporine
    Cytotoxicity against human Raji cells
    Cytotoxicity against human Raji cells
    		[PMID: 25316317]
    Rec1 IC50
    0.0255 μM
    Compound: Staurosporine
    Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Cytotoxicity against human REC1 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    SF-268 GI50
    0.044 μM
    Compound: Staurosporine
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
    		[PMID: 21513294]
    SR GI50
    6.29 μM
    Compound: Staurosporine
    Cytotoxicity against human SR cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    Cytotoxicity against human SR cells assessed as cell growth inhibition incubated for 4 days by MTT assay
    		[PMID: 37506545]
    SR IC50
    2.62 μM
    Compound: Staurosporine
    Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay
    Antiproliferative activity against human SR cells assessed as inhibition of cell growth incubated for 2 to 4 hrs by MTT assay
    		[PMID: 38389871]
    ST486 IC50
    0.007 μM
    Compound: Staurosporine
    Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay
    		[PMID: 22182929]
    SUP-B15 EC50
    0.55 μM
    Compound: STS
    Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    SW 1116 EC50
    24.92 μg/mL
    Compound: Staurosporine
    Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay
    		[PMID: 21889345]
    SW 1116 IC50
    4.18 μM
    Compound: Staurosporine
    Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay
    Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay
    		[PMID: 24286761]
    SW 1116 IC50
    4.95 μM
    Compound: Staurosporine
    Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method
    Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method
    		[PMID: 23018096]
    SW 1116 IC50
    8.32 μM
    Compound: Staurosporine
    Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay
    Inhibition of telomerase in human SW1116 cells after 24 hrs by TRAP-PCR-ELISA assay
    		[PMID: 21962523]
    SW-1736 EC50
    0.2 μM
    Compound: STS
    Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
    		[PMID: 30840925]
    SW480 IC50
    < 0.1 μM
    Compound: Staurosporine
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31740249]
    Sf21 IC50
    0.002 μM
    Compound: Staurosporine
    Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method
    Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method
    		[PMID: 27137359]
    Sf21 IC50
    0.027 μM
    Compound: staurosporine
    Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM
    Inhibition of human CHK2 kinase expressed in insect Sf21 cells using phospho-CREBtide as substrate at 30 uM
    		[PMID: 21334796]
    Sf21 IC50
    0.039 μM
    Compound: staurosporine
    Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM
    Inhibition of human recombinant IKK-alpha expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM
    		[PMID: 21334796]
    Sf21 IC50
    0.49 μM
    Compound: staurosporine
    Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM
    Inhibition of human recombinant IKK-beta expressed in insect Sf21 cells using phospho-Ulight-IkappaB-alpha as substrate at 30 uM
    		[PMID: 21334796]
    Sf21 IC50
    1325 nM
    Compound: Staurosporine
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 5 mins by time resolved-fluorescent assay
    		[PMID: 21441024]
    Sf21 IC50
    1533 nM
    Compound: Staurosporine
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 30 mins by time resolved-fluorescent assay
    		[PMID: 21441024]
    Sf21 IC50
    1646 nM
    Compound: Staurosporine
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 60 mins by time resolved-fluorescent assay
    		[PMID: 21441024]
    Sf21 IC50
    1701 nM
    Compound: Staurosporine
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay
    Inhibition of IGF-induced autophosphosphorylation of GST-tagged human IGF1R expressed in baculovirus-SF21 cell system preincubated for 10 mins by time resolved-fluorescent assay
    		[PMID: 21441024]
    Sf21 IC50
    6 nM
    Compound: 2
    Inhibition of JAK3 expressed in Sf21 cells
    Inhibition of JAK3 expressed in Sf21 cells
    		[PMID: 17088059]
    Sf21 IC50
    6 nM
    Compound: staurosporine
    Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation
    Inhibition of JAK3 expressed in insect Sf21 cells assessed as inhibition of biotinylated substrate phosphorylation
    		[PMID: 19427203]
    Sf9 IC50
    0.003 μM
    Compound: staurosporine
    Inhibition of human Syk expressed in Sf9 cells
    Inhibition of human Syk expressed in Sf9 cells
    		[PMID: 18823784]
    Sf9 IC50
    0.0039 μM
    Compound: Staurosporine
    Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay
    Inhibition of N-terminal His-tagged recombinant human AXL (473 to end amino acids) expressed by baculovirus in Sf9 cells using axltide substrate and ATP by ADP-Glo luminescence assay
    		[PMID: 30340900]
    Sf9 IC50
    0.005 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    0.015 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    0.036 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 10 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    0.053 μM
    Compound: staurosporine
    Inhibition of human ZAP70 expressed in Sf9 cells
    Inhibition of human ZAP70 expressed in Sf9 cells
    		[PMID: 18823784]
    Sf9 IC50
    0.083 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 10 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    0.27 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 100 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    0.51 μM
    Compound: Staurosporine
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP
    Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 100 umol/L ATP
    		[PMID: 17315853]
    Sf9 IC50
    1.2 nM
    Compound: Staurosporine
    Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay
    Inhibition of N-terminal GST tagged recombinant full-length human CHK1 expressed in baculovirus Sf9 insect cells after 10 mins by luminescent ADP-Glo assay
    		[PMID: 27089211]
    Sf9 IC50
    2.3 μM
    Compound: staurosporine
    Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay
    Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay
    		[PMID: 20580552]
    Sf9 IC50
    > 18.5 μM
    Compound: Staurosporine
    Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay
    Inhibition of human recombinant ALK5 expressed in insect Sf9 cells using casein as substrate by radioisotopic assay
    		[PMID: 24786585]
    Sf9 IC50
    2.0 x 10-8 M
    Compound: staurosporine
    Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
    Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
    		[PMID: 9873605]
    Splenocyte IC50
    0.4 μM
    Compound: 1 (Staurosporine)
    In vitro for inhibitory activity against tyrosine specific protein kinase from murine spleen cells (T-kinase)
    In vitro for inhibitory activity against tyrosine specific protein kinase from murine spleen cells (T-kinase)
    		10.1016/S0960-894X(01)80995-1
    T47D IC50
    11.7 μM
    Compound: Staurosporine
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as reduction in cell viability after 3 hrs by MTT assay
    		[PMID: 33962153]
    T47D IC50
    4.52 μM
    Compound: Staurosporine
    Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
    Cytotoxicity against human T47D cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay
    		[PMID: 32044580]
    T47D IC50
    4.849 μM
    Compound: Staurosporine
    Cytotoxicity against human T47D cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human T47D cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38107182]
    T47D IC50
    7.12 μM
    Compound: Staurosporine
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human T47D cells incubated for 48 hrs by MTT assay
    		[PMID: 37501287]
    TERT-RPE1 IC50
    0.0055 μM
    Compound: Staurosporine
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis
    		[PMID: 33248847]
    TERT-RPE1 IC50
    0.25 μM
    Compound: Staurosporine
    Cytostatic activity against human hTERT-RPE1 cells
    Cytostatic activity against human hTERT-RPE1 cells
    		[PMID: 30738653]
    U-87MG ATCC IC50
    0.02 μM
    Compound: STS
    Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth
    Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth
    		[PMID: 32201021]
    U-937 IC50
    2 μM
    Compound: staurosporine
    Cytotoxicity against human U937 cells
    Cytotoxicity against human U937 cells
    		[PMID: 17088067]
    UoC-B1 EC50
    2 μM
    Compound: STS
    Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Antiproliferative activity against human UOCB1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30840453]
    Vero IC50
    0.0024 μM
    Compound: Staurosporine
    Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against African green monkey Vero cells after 2 days by CellTiter-Glo luminescent cell viability assay
    		[PMID: 28993106]
    Vero IC50
    0.028 μM
    Compound: Staurosporine
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30743094]
    WI-38 IC50
    24.41 μM
    Compound: Staurosporine
    Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay
    Cytotoxicity against human WI-38 cells assessed as cell viability measured by MTT assay
    		[PMID: 34246754]
    Z-138 IC50
    0.0067 μM
    Compound: Staurosporine
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis
    		[PMID: 33248847]
    Z-138 IC50
    0.018 μM
    Compound: Staurosporine
    Antiproliferative activity against human Z138 cells
    Antiproliferative activity against human Z138 cells
    		[PMID: 31005446]
    Z-138 IC50
    0.02 μM
    Compound: STS
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay
    		[PMID: 32832030]
    Z-138 IC50
    0.0418 μM
    Compound: Staurosporine
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
    		[PMID: 34352711]
    Z-138 IC50
    21.5 μM
    Compound: Staurosporine
    Cytostatic activity against human Z138 cells
    Cytostatic activity against human Z138 cells
    		[PMID: 30738653]
    In Vitro

    Staurosporine, widely used as a protein kinase C (PKC) inhibitor with a broad spectrum of activity, is an alkaloid which can be isolated from the culture broth of Streptomyces staurospores. MC3T3E-1 osteoblasts, expose to Staurosporine (100 nM) for 12 h, release an amount of LDH (12.4±3.1%) that is similar to that release by the control cells(10.0±2.4%), indicating the relative absence of lytic death, which occurs in necrosis. In addition, treatment with Staurosporine (100 nM) results in morphological changes, characteristic of apoptosis: a brightblue fluorescent condensed nuclei seen through a fluorescence microscope after Hoechst 33258-staining, and a reduction of cell volume[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Staurosporine Related Antibodies
    In Vivo

    The inhibitory effect of Staurosporine is statistically significant at around Wk 10 of tumor promotion. Although statistically significant inhibition is not obtained with 10 ng of Staurosporine in later weeks of the experiment, a decreasing tendency in the percentages of tumor bearing mice and in average numbers of tumors per mouse is apparent. Thus, Staurosporine slightly inhibits tumor promotion of Teleocidin, even at the dose at which Staurosporine itself induced tumors[3]. Staurosponne (0.05 and 0.1 mg/kg intraperitoneal) attenuates the impaired perlormance of water maze and passive avoidance tasks, even though the drug administration began 2 weeks after the lesion. Moreover, Staurosporine (0.1 mg/kg) partially reversed the decrease of choline acetyltransferase activity in the fronto-parietal cortex induced by basal forebrain-lesion. These results suggest that Staurosporine attenuates impairment of learning through reversal of damage to cholinergic neurons induced by basal forebrain-lesion[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    466.53

    Formula

    C28H26N4O3
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(NC1)C2=C1C3=C(C4=C2C5=C(C=CC=C5)N4[C@H]6C[C@@H](NC)[C@@H](OC)[C@]7(C)O6)N7C8=CC=CC=C83
    Structure Classification
    Initial Source

    Streptomyces staurosporeus
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 62.5 mg/mL (133.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1435 mL 10.7174 mL 21.4348 mL
    5 mM 0.4287 mL 2.1435 mL 4.2870 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.46 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC-Na/saline water

      Solubility: 3.33 mg/mL (7.14 mM); Suspension solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.77%

    SDS (419 KB)

    COA (269 KB) HNMR (196 KB) LCMS (136 KB) Elemental Analysis Report (126 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [3][4]

    Mice[3]
    Female CD-I mice are used. Various amounts of Staurosporine in 10 μL of acetone are applied to the ears of 8-wk-old CD-I mice. The extent of irritation is expressed as the minimum dose of the compound causing irritation. Induction of HOC in Mouse Skin Staurosporine in 0.1 mL of acetone is applied to the skin of the backs of CD-I mice, and a crude enzyme extract is obtained from the skin 18 h later. HDC activity is expressed as pmol of CO2 released per mg of protein per l h of incubation. Induction of ODC in Mouse Skin Staurosporine in 0.2 mL of acetone is applied to the skin of the backs of CD-I mice. After 4 h, a crude enzyme extract is prepared from the epidermis, and its ODC activity is measured. Enzyme activity is expressed as nmol of CO2 per mg of protein per 30 min of incubation.
    Rats[4]
    Male Kbl Wistar rats(weighing 270 to 310 g) are used. In the group which is given Staurosporine for 2 weeks, the water maze task and Staurosporine administration are started 2 weeks after the BF-lesion, and the passive avoidance task is carried out 4 weeks after the BFlesion. The rat received Staurosporine at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg (i.p., N=10 in each group for 2 weeks) 30 mm prior to the water maze training sessions and the passive avoidance task acquisitiontrial. In the group which is given Staurosporine for 4 weeks, the drug is first given 2 weeks after the BF-lesion. The water maze task is carried out 4 weeks after the BF-lesion. The passive avoidance task is carried out 6 weeks after the BF-lesion. The rat received Staurosporine at 0.05, 0.1, and 0.2 mg/kg (i.p., N=10 in each group) once a day for 2 weeks before training, and for 2 weeks after the water maze training sessions and the passive avoidance task acquisition trial. Staurosporine is suspended in 0.3% of sodium carboxymethyl cellulose. The vehicle is administered to the non-lesioned controls and the lesioned controls on the same schedule as the Staurosporine-treated animals.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1435 mL 10.7174 mL 21.4348 mL 53.5871 mL
    5 mM 0.4287 mL 2.1435 mL 4.2870 mL 10.7174 mL
    10 mM 0.2143 mL 1.0717 mL 2.1435 mL 5.3587 mL
    15 mM 0.1429 mL 0.7145 mL 1.4290 mL 3.5725 mL
    20 mM 0.1072 mL 0.5359 mL 1.0717 mL 2.6794 mL
    25 mM 0.0857 mL 0.4287 mL 0.8574 mL 2.1435 mL
    30 mM 0.0714 mL 0.3572 mL 0.7145 mL 1.7862 mL
    40 mM 0.0536 mL 0.2679 mL 0.5359 mL 1.3397 mL
    50 mM 0.0429 mL 0.2143 mL 0.4287 mL 1.0717 mL
    60 mM 0.0357 mL 0.1786 mL 0.3572 mL 0.8931 mL
    80 mM 0.0268 mL 0.1340 mL 0.2679 mL 0.6698 mL
    100 mM 0.0214 mL 0.1072 mL 0.2143 mL 0.5359 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Staurosporine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Staurosporine62996-74-1Antibiotic AM-2282 STS AM-2282Antibiotic AM2282Antibiotic AM 2282AM2282AM 2282AM-2282PKCPKAApoptosisBacterialFungalAntibioticProtein kinase CProtein kinase AInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Staurosporine
    Cat. No.:
    HY-15141
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Korean - KR (419 KB) Portuguese - PT (419 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.